Table 5.
Cellular biomarkers and oxidative damage and their association to SIL and cervical cancer development
| NSILa | LSIL | HSIL | CC | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| OR | OR | CI | p | OR | CI | p | OR | CI | p | |
| TOP2A/MCM2 | 1.0 | 22.5 | 9.3–54.1 | <0.001 | 900.8 | 240.3–3376 | <0.001 | 2484 | 507–∞ | <0.001 |
| p16INK4a | 1.0 | 10.1 | 4.6–22.2 | <0.001 | 138.1 | 42.6–447.8 | <0.001 | 320.6 | 75.0–∞ | <0.001 |
| Cyclin E | 1.0 | 10.0 | 4.6–21.3 | <0.001 | 109.9 | 36.3–333.2 | <0.001 | 533.0 | 123.3–∞ | <0.001 |
| Ki-67 | 1.0 | 6.7 | 3.4–13.2 | <0.001 | 121.4 | 40.9–360.3 | <0.001 | 522.8 | 121.5–∞ | <0.001 |
| Telomerase | 1.0 | 13.7 | 6.1–30.7 | <0.001 | 85.7 | 26.2–280.5 | <0.001 | 165.9 | 39.2–∞ | <0.001 |
| RI-5 | 1.0 | 58 | 18.5–186.1 | <0.001 | 4012 | 755–21,323 | <0.001 | 8290 | 1309–∞ | <0.001 |
| RI-4 | 1.0 | 29.5 | 11.3–76.8 | <0.001 | 1482 | 340.8–6461 | <0.001 | 3878 | 691–∞ | <0.001 |
| RI-3 | 1.0 | 40.2 | 14.2–114.4 | <0.001 | 2924 | 592–14,429 | <0.001 | 5913 | 998–∞ | <0.001 |
| RI-2 | 1.0 | 24.5 | 9.9–60.8 | <0.001 | 1290 | 306.8–5429 | <0.001 | 3020 | 526–∞ | <0.001 |
| ROS | 1.0 | 1.8 | 1.4–2.3 | <0.001 | 1.2 | 0.8–1.8 | 0.30 | 0.5 | 0.3–0.8 | 0.004 |
| 8-OHdG | 1.0 | 4.4 | 2.7–7.2 | <0.001 | 3.6 | 1.9–6.6 | <0.001 | 5.3 | 2.8–10.0 | <0.001 |
NSIL Non-squamous intraepithelial lesions, LSIL Low-grade squamous intraepithelial lesions, HSIL High-grade squamous intraepithelial lesions, CC Cervical cancer, OR Odds ratio, CI Confidence interval, RI Risk index; RI-5 analysis with TOP2A/MCM2, p16INK4a, cyclin E, Ki-67, and telomerase; RI-4 analysis with TOP2A/MCM2, p16INK4a, cyclin E, and Ki-67; RI-3 analysis with TOP2A/MCM2, p16INK4a, and cyclin E; RI-2 analysis with TOP2A/MCM2 and p16INK4a OR adjusted by age and HPV infection by oncogenic risk (HPV negative, HR, PHR, LHR, and UHR) areference category